Evidence map›Paper›PMID 32917255›Full record

ArticleParasites & vectors2020

Efficacy of Fludora® Fusion (a mixture of deltamethrin and clothianidin) for indoor residual spraying against pyrethroid-resistant malaria vectors: laboratory and experimental hut evaluation.

Augustin Fongnikin, Nadia Houeto, Abel Agbevo, Abibath Odjo, Thomas Syme, Raphael N'Guessan, Corine Ngufor

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Functional Validation of Endogenous Redox PartnerInternational journal of molecular sciences · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Augustin FongnikinCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Nadia HouetoCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Abel AgbevoCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Abibath OdjoCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Thomas SymeLondon School of Hygiene and Tropical Medicine (LSHTM), London, UK.
Raphael N'GuessanLondon School of Hygiene and Tropical Medicine (LSHTM), London, UK.
Corine NguforLondon School of Hygiene and Tropical Medicine (LSHTM), London, UK. corine.ngufor@lshtm.ac.uk.ORCID http://orcid.org/0000-0002-7755-9609
London School of Hygiene & Tropical Medicine · GBMalaria Consortium · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA new generation of IRS insecticides which can provide improved and prolonged control of pyrethroid-resistant malaria vector populations are being developed. Fludora® Fusion is a new IRS insecticide containing a mixture of deltamethrin and clothianidin, a neonicotinoid.

methodsThe efficacy of Fludora® Fusion IRS was evaluated over 11-12 months on concrete and mud substrates in laboratory bioassays and experimental huts against wild free-flying pyrethroid-resistant Anopheles gambiae (sensu lato) in Cové, Benin. A comparison was made with the two active ingredients of the mixture; clothianidin and deltamethrin, applied alone. CDC bottle bioassays were also performed to investigate resistance to clothianidin in the wild vector population.

resultsFludora® Fusion induced > 80% laboratory cone bioassay mortality with both susceptible and pyrethroid-resistant An. gambiae (s.l.) for 7-9 months on concrete block substrates and 12 months on mud block substrates. The vector population at the experimental hut site was fully susceptible to clothianidin in CDC bottle bioassays. Overall mortality rates of wild free-flying pyrethroid-resistant An. gambiae (s.l.) entering the experimental huts during the 11-month trial were < 15% with deltamethrin and significantly higher with Fludora® Fusion (69-71%) and clothianidin alone (72-78%). Initial high experimental hut mortality rates with Fludora® Fusion (> 80%) only declined by 50% after 8 months. Monthly in situ wall cone bioassay mortality of susceptible mosquitoes was > 80% for 9-12 months with Fludora® Fusion and clothianidin alone. Fludora® Fusion induced significantly higher levels of early exiting of mosquitoes compared to clothianidin alone (55-60% vs 37-38%, P < 0.05).

conclusionsIndoor residual spraying with Fludora® Fusion induced high and prolonged mortality of wild pyrethroid-resistant malaria vectors for 7-10 months mostly due to the clothianidin component and substantial early exiting of mosquitoes from treated huts due to the pyrethroid component. Fludora® Fusion is an important addition to the current portfolio of IRS insecticides with the potential to significantly reduce transmission of malaria by pyrethroid-resistant mosquito vectors.

Indexed as

AnimalsAnophelesBeninGuanidinesHumansInsecticide ResistanceInsecticidesLaboratoriesMalariaMosquito ControlMosquito VectorsNeonicotinoidsNitrilesPyrethrinsThiazolesclothianidindecamethrinGuanidinesInsecticidesNeonicotinoidsNitrilesPyrethrinsThiazolesAnophelesClothianidinCovéExperimental hutsFludoraFludora® FusionFormulationsIndoor residual sprayingIRS block substratesIRS mixturesMalaria vectorsMixturesMosquito controlNeonicotinoidsPyrethroid resistanceVector control

Identifiers

PMID32917255
PMCPMC7488472
OpenAlexW3086704886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.